Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SomatoKine trial initiated by Insmed
The clinical trial is an open-label, dose-ranging study designed to evaluate the safety and efficacy of SomatoKine for 16 weeks in 10 patients with Type A Extreme Insulin
The clinical trial is an open-label, dose-ranging study designed to evaluate the safety and efficacy of SomatoKine for 16 weeks in 10 patients with Type A Extreme Insulin
Chorea is the most visible and common of the motor symptoms observed in patients with Huntington’s disease. The condition is characterized by brief, irregular contractions that are not
These non-randomized, dose-escalation studies will evaluate the safety and tolerability, pharmacokinetics, and anticancer activity of AP23573 in combination with paclitaxel or capecitabine. The primary goal of these studies
CG0070 is the first “armed” oncolytic virus therapy developed by Genesys. Extensive preclinical studies have shown that CG0070 can potentially destroy cancer cells by two different mechanisms: direct
A group of early life science companies; ARCH Venture Partners, Venrock Associates, 5AM Ventures, Aravis Ventures and the Washington Research Foundation, have committed approximately $10 million to the
The study, recently published in the Neurobiology of Aging, is a joint effort between scientists at the University of British Columbia and University of Saskatchewan. The scientists reviewed
The scientists uncovered a clue about the causes of dementia in Huntington’s disease by showing that mice susceptible to Huntington’s disease have problems with learning and memory before
The study is believed to be the first to suggest future therapies for heart failure using chemical cofactors that control the enzymes’ action. Nitric oxide (NO)’s extensive portfolio
Genentech, majority-owned by Swiss drugmaker Roche, performed the research comparing Herceptin (trastuzumab) and chemotherapy to chemotherapy alone. Their results indicate patients not only benefited from a decreased reoccurrence
Neurochem’s independent safety review board (ISRB) for Alzhemed is made up of independent medical experts who monitor and evaluate the safety of patients taking part in the Alzhemed